• Thu. Apr 16th, 2026

biopharma

  • Home
  • Smart bet, only option, or both?: Biopharma R&D turns to AI

Smart bet, only option, or both?: Biopharma R&D turns to AI

Discover how artificial intelligence is reshaping drug discovery, clinical trials, and regulatory processes – and what leaders must do to scale its impact. The pharmaceutical and biotechnology industry faces persistent…

Boosting biopharma R&D performance with a next-generation technology stack

Amid growing complexities, escalating costs, and a heightened demand for innovative therapies, biopharmaceutical R&D organizations are under pressure to find ways to boost their productivity. Preclinical studies are increasingly using…